Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of lactulose to prevention or treatment of postmenopausal osteoporosis

A technology for osteoporosis and osteoporosis, which is applied in the fields of medical preparations containing active ingredients, bone diseases, organic active ingredients, etc. It can solve the problems of prevention and treatment of osteoporosis, and achieve stable curative effect. , the effect of preventing degradation

Inactive Publication Date: 2019-06-07
陈晓
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Therefore, lactulose, as an effective intestinal flora regulator and short-chain fatty acid metabolism substrate, is likely to have a positive regulatory effect on bone metabolism, but no one has effectively studied this, let alone its relationship with Prevention and treatment of postmenopausal osteoporosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lactulose to prevention or treatment of postmenopausal osteoporosis
  • Application of lactulose to prevention or treatment of postmenopausal osteoporosis
  • Application of lactulose to prevention or treatment of postmenopausal osteoporosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1. Lactulose has an inhibitory effect on bone loss after ovariectomy in C57 mice 1. Experimental materials:

[0040] 6-8-week-old female C57 mice were purchased from the Experimental Animal Center of the Second Military Medical University of the Chinese People's Liberation Army;

[0041] Lactulose oral solution (667 mg / mL) was purchased from Abbott Biologicals B.V., Netherlands.

[0042] 2. Experimental method:

[0043] 1. Grouping and modeling:

[0044] Sham operation group: open the skin and fascia from the back, suture after exposing the ovary, and then take normal saline (0.3mL / 10g) orally for 6 weeks;

[0045] Sham operation + lactulose group: open the skin and fascia from the back, suture after exposing the ovaries, and then take lactulose solution (0.3mL / 10g) orally for 6 weeks;

[0046] Ovariectomy group: Open the skin and fascia from the back, remove the ovaries, and then take normal saline (0.3mL / 10g) orally for 6 weeks;

[0047] Ovariectomy+lactul...

Embodiment 2

[0064] Example 2. Short-term administration of lactulose can reduce bone resorption index in normal population

[0065] 1. Study population

[0066] Healthy adult men under the age of 35, a total of 8 people

[0067] 2. Research methods

[0068] On Sunday morning, blood was drawn from all subjects, and the serum was preserved after centrifugation; lactulose (7.5mL / day) was taken every morning from the second day of blood drawing for a total of 2 weeks; blood was drawn again after 2 weeks, and centrifuged to obtain serum.

[0069] All sera were measured for CTX-1 levels by ELISA (Immunodiagnosticsystems detection kit https: / / www.idsplc.com / products / serum-crosslaps-ctx-i-elisa-2 / , McClung MR et al., Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of aphase 2 clinical trial. Osteoporos Int. 2013 Jan; 24(1): 227-35).

[0070] 3. Research results

[0071] Figure 9 The human serum level before and after taking lactulose f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of biopharmaceutical engineering, and provides an application of lactulose to prevention or treatment of postmenopausal osteoporosis. HE slicing and Micro-CT results prove that when the lactulose is taken orally, the bone mass of normal mice can be increased, and sclerotin loss caused by ovariotomy can be restrained. The intestine flora structure can beobviously changed, and the SCFA content of excrement and urine can be increased. Besides, after the ovariotomy, the lever of inflammatory factors in serum is increased, and after the lactulose is taken, the level is obviously restrained; and in addition, clinical test on small-sample healthy crowds proves that when the lactulose is taken for a short term, the bone absorption index can be reduced.Test proves that the lactulose can perform positive regulation on the bone metabolism, and can be used as an active component for preventing or treating osteoporosis particularly the postmenopausal osteoporosis, and a new thinking is provided for prevention and treatment of the postmenopausal osteoporosis.

Description

technical field [0001] The invention relates to the technical field of lactulose application, in particular to the application of lactulose in the preparation of drugs for positive regulation of bone metabolism, especially in the prevention or treatment of postmenopausal osteoporosis. Background technique [0002] Bone metabolism is subject to complex and precise regulation by the body. Existing studies have shown that the intestinal immune system, intestinal flora and intestinal flora metabolites are directly or indirectly involved in the regulation of osteoblast and osteoclast proliferation and differentiation and other bone metabolic processes. It plays an important role in both physiological bone metabolism and pathological bone diseases. [0003] Postmenopausal osteoporosis (Postmemopausal Osteoporosis, OP) is caused by estrogen deficiency in postmenopausal women, resulting in hyperactivity of osteoclasts, accelerated bone turnover rate, and continuous loss of net bone ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7016A61P19/10
Inventor 陈晓
Owner 陈晓
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com